Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?
Author:
Funder
National Heart and Lung Institute
National Institute on Aging
Publisher
Springer Science and Business Media LLC
Subject
Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11906-022-01229-x.pdf
Reference140 articles.
1. • Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591–603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667.
2. Ferrari R, Rosano GM. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context. Int J Cardiol. 2013;166(2):286–8. https://doi.org/10.1016/j.ijcard.2013.01.027.
3. Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7(1):51–3. https://doi.org/10.4103/2229-3485.173773.
4. •• Turnbull F, Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35. https://doi.org/10.1016/s0140-6736(03)14739-3.
5. Akobeng AK. Understanding measures of treatment effect in clinical trials. Arch Dis Child. 2005;90(1):54–6. https://doi.org/10.1136/adc.2004.052233.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chymase in Plasma and Urine Extracellular Vesicles: Novel Biomarkers for Primary Hypertension;2023-11-10
2. Is chymase 1 a therapeutic target in cardiovascular disease?;Expert Opinion on Therapeutic Targets;2023-08-03
3. Increased CaMKII activation and contrast changes of cardiac β1-and β3-Adrenergic signaling pathways in a humanized angiotensinogen model of hypertension;Heliyon;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3